% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Edsj:282367,
author = {A. Edsjö and L. Holmquist and B. Geoerger and F. Nowak and
G. Gomon and C. Alix-Panabières and C. Ploeger and U.
Lassen and C. Le Tourneau and J. Lehtiö and P. A. Ott and
A. von Deimling$^*$ and S. Fröhling$^*$ and E. Voest and F.
Klauschen$^*$ and R. Dienstmann and A. Alshibany and L. L.
Siu and A. Stenzinger},
title = {{P}recision cancer medicine: {C}oncepts, current practice,
and future developments.},
journal = {Journal of internal medicine},
volume = {294},
number = {4},
issn = {0001-6101},
address = {Oxford [u.a.]},
publisher = {Wiley-Blackwell},
reportid = {DKFZ-2023-01749},
pages = {455-481},
year = {2023},
note = {2023 Oct;294(4):455-481},
abstract = {Precision cancer medicine is a multidisciplinary team
effort that requires involvement and commitment of many
stakeholders including the society at large. Building on the
success of significant advances in precision therapy for
oncological patients over the last two decades, future
developments will be significantly shaped by improvements in
scalable molecular diagnostics in which increasingly complex
multilayered datasets require transformation into clinically
useful information guiding patient management at fast
turnaround times. Adaptive profiling strategies involving
tissue- and liquid-based testing that account for the
immense plasticity of cancer during the patient's journey
and also include early detection approaches are already
finding their way into clinical routine and will become
paramount. A second major driver is the development of smart
clinical trials and trial concepts which, complemented by
real-world evidence, rapidly broaden the spectrum of
therapeutic options. Tight coordination with regulatory
agencies and health technology assessment bodies is crucial
in this context. Multicentric networks operating nationally
and internationally are key in implementing precision
oncology in clinical practice and support developing and
improving the ecosystem and framework needed to turn
invocation into benefits for patients. The review provides
an overview of the diagnostic tools, innovative clinical
studies, and collaborative efforts needed to realize
precision cancer medicine.},
subtyp = {Review Article},
keywords = {clinical trials (Other) / molecular diagnostics (Other) /
personalized oncology (Other) / precision cancer medicine
(Other) / precision medicine networks (Other)},
cin = {B300 / B340 / HD01 / BE01 / MU01},
ddc = {610},
cid = {I:(DE-He78)B300-20160331 / I:(DE-He78)B340-20160331 /
I:(DE-He78)HD01-20160331 / I:(DE-He78)BE01-20160331 /
I:(DE-He78)MU01-20160331},
pnm = {312 - Funktionelle und strukturelle Genomforschung
(POF4-312)},
pid = {G:(DE-HGF)POF4-312},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:37641393},
doi = {10.1111/joim.13709},
url = {https://inrepo02.dkfz.de/record/282367},
}